Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 14/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160855 | 0.85 | MEN1 (0.47) | SLC6A9PRMT5WDR77POLBSMN1; SMN2 | |
| SCHEMBL6573147 | 0.84 | OPRD1 (0.36) | SLC6A9PRMT5WDR77ALDH1A1MAPT | |
| SCHEMBL7176616 | 0.80 | PRMT5 (0.39) | SLC6A9PRMT5WDR77ALDH1A1MAPT | |
| SCHEMBL7157652 | 0.74 | PRMT5 (0.46) | PRMT5WDR77SMN1; SMN2 | |
| SCHEMBL7162717 | 0.72 | PRMT5 (0.48) | PRMT5WDR77 | |
| SCHEMBL7156020 | 0.72 | RAB9A (0.39) | SLC6A9PRMT5WDR77POLBSMN1; SMN2 | |
| SCHEMBL2386276 | 0.71 | GABBR2 (0.57) | POLBSMN1; SMN2TDP1MAPT | |
| Tetraxetan SCHEMBL861961 | 0.71 | SLC6A9 (0.49) | SLC6A9POLBSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL7159605 | 0.69 | MAPT (0.60) | POLBSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18118422 | 0.69 | OPRK1 (0.52) | SLC6A9POLBSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777498-B1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| EP-0768898-B1 | CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME | SCHERING AG (DE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1037671-B1 | POLYROTAXANES | SCHERING AG (DE) | 2003-02-05 | — | — | EP | disclosed |
| EP-0917474-B1 | PSEUDOPOLYROTAXANES | SCHERING AG (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| US-6248306-B1 | MEDICAL DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6113880-A | Polyrotaxane derivatives for x-ray and nuclear magnetic resonance imaging | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| US-6068831-A | NEW METAL COMPLEX-CONTAINING OR IODINE-CONTAINING BENZENE DERIVATIVES THAT CONTAIN PSEUDOPOLYROTAXANES THAT ARE VALUABLE COMPOUNDS FOR DIAGNOSTIC RADIOLOGY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-30 | — | — | US | disclosed |
| EP-0917474-A2 | PSEUDOPOLYROTAXANES | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998001163-A2 | PSEUDOPOLYROTAXANES | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-01-15 | — | — | WO | disclosed |
| EP-0770146-A1 | CONJUGATES OF METAL COMPLEXES AND OLIGONUCLEOTIDES, WHICH SPECIFICALLY BOND TO SPECIFIC TARGET STRUCTURES, AGENTS CONTAINING THESE CONJUGATES, THEIR USE IN NMR DIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-02 | — | — | EP | disclosed |
| EP-0768898-A1 | CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996002669-A1 | CONJUGATES OF METAL COMPLEXES AND OLIGONUCLEOTIDES, WHICH SPECIFICALLY BOND TO SPECIFIC TARGET STRUCTURES, AGENTS CONTAINING THESE CONJUGATES, THEIR USE IN NMR DIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996001655-A1 | CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | DCLRE1B, RNASE1, DCLRE1A | SLC6A9 3136/4885PRMT5 2903/4885WDR77 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.